The Promises Behind Terns' Multi-Pronged Pipeline

Terns Pharmaceuticals (NASDAQ: TERN) is a pharmaceutical company that specializes in multiple treatments for a liver condition called non-alcoholic steatohepatitis, or NASH. Based in Foster City, Calif., since its founding in 2016, Terns is currently working on three drugs to treat NASH via different mechanisms of action.

And while it's new to the market, having had its initial public offering just last month, there are reasons to keep an eye on this business. From its IPO price of $17 per share, the stock has reached more than $21 as of this writing. According to recent developments outlined in its February investor presentation, there is reason to believe that the stock could go higher.

Image source: Getty Images.

Source Fool.com